Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA


Brahe C. H., Ornbjerg L. M., Jacobsson L., Nissen M. J., Kristianslund E. K., Mann H., ...More

RHEUMATOLOGY, vol.59, no.7, pp.1640-1650, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 7
  • Publication Date: 2020
  • Doi Number: 10.1093/rheumatology/kez427
  • Journal Name: RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Page Numbers: pp.1640-1650
  • Keywords: psoriatic arthritis, spondyloarthritis, TNFi, effectiveness, drug survival, response, epidemiology, register, DAS28, DAPSA28, NECROSIS-FACTOR INHIBITORS, MODIFYING ANTIRHEUMATIC DRUGS, PSORIATIC-ARTHRITIS, RHEUMATOID-ARTHRITIS, PREDICTORS THEREOF, CLINICAL-PRACTICE, INFLIXIMAB, SURVIVAL, THERAPY, COMEDICATION
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective. To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naive patients with PsA.